Abstract
Melanoma is a common aggressive skin cancer. Its numerous genetic mutations have become rich targets for systemic therapy with chemotherapy or immunotherapy. Surgery is the best initial treatment. Completion nodal dissection for sentinel node positive patients decrease regional occurrence but no survival benefit was found in a few studies. Radiotherapy (RT) is used as primary, adjuvant and palliative treatment. Specific scenarios with unknown primary, head and neck melanomas, and distant metastases are discussed. Systemic therapy includes molecular therapy based on diver mutation or immunotherapy. Treatment guidelines should be utilized by the multidisciplinary team to aid treatment decision making. Future improvement in outcome can only be achieved by enrollment of patient into clinical trials and therefore should be encouraged. Future research will be along the line of immunotherapy, target therapy, hyperthermia, nanoparticles, neutron, and radioisotope treatments.
Keywords: Sentinel node biopsy, systemic therapy, chemotherapy, radiotherapy, node dissection, targeted therapy, treatment, sites.
Current Cancer Therapy Reviews
Title:Melanoma
Volume: 12 Issue: 3
Author(s): Vamsee Torri, Wojciech Dolata, Khanh Vu, Arbind Dubey, Bryan Brunet and Patricia Tai
Affiliation:
Keywords: Sentinel node biopsy, systemic therapy, chemotherapy, radiotherapy, node dissection, targeted therapy, treatment, sites.
Abstract: Melanoma is a common aggressive skin cancer. Its numerous genetic mutations have become rich targets for systemic therapy with chemotherapy or immunotherapy. Surgery is the best initial treatment. Completion nodal dissection for sentinel node positive patients decrease regional occurrence but no survival benefit was found in a few studies. Radiotherapy (RT) is used as primary, adjuvant and palliative treatment. Specific scenarios with unknown primary, head and neck melanomas, and distant metastases are discussed. Systemic therapy includes molecular therapy based on diver mutation or immunotherapy. Treatment guidelines should be utilized by the multidisciplinary team to aid treatment decision making. Future improvement in outcome can only be achieved by enrollment of patient into clinical trials and therefore should be encouraged. Future research will be along the line of immunotherapy, target therapy, hyperthermia, nanoparticles, neutron, and radioisotope treatments.
Export Options
About this article
Cite this article as:
Torri Vamsee, Dolata Wojciech, Vu Khanh, Dubey Arbind, Brunet Bryan and Tai Patricia, Melanoma, Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573394713666170113115759
DOI https://dx.doi.org/10.2174/1573394713666170113115759 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry TGF-Beta: a Master Switch in Tumor Immunity
Current Pharmaceutical Design Viral Origins of Human Cancer
Current Medicinal Chemistry Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres
Anti-Cancer Agents in Medicinal Chemistry Cell Compatibility of an Eposimal Vector Mediated by the Characteristic Motifs of Matrix Attachment Regions
Current Gene Therapy Structural Aspects of Peptides with Immunomodulating Activity
Mini-Reviews in Medicinal Chemistry Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Plant Extracts as a Natural Source of Bioactive Compounds and Potential Remedy for the Treatment of Certain Skin Diseases
Current Pharmaceutical Design Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Incorporating Fatty Acid-Modified Polyethylenimine
Current Pharmaceutical Biotechnology Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer
Protein & Peptide Letters HIV-Antigens Charged on Phosphorus Dendrimers as Tools for Tolerogenic Dendritic Cells-Based Immunotherapy
Current Medicinal Chemistry Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Synthesis and Biological Evaluation of Licofelone Derivatives as Anticancer and Anti-inflammatory Agents
Letters in Drug Design & Discovery Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry